SYBE.US SYBLEU INC.
- Market cap
- USD 584K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Dec 2023.
Is SYBE.US undervalued?
Graham numberThe Graham number of SYBLEU INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SYBLEU INC. fundamental analysis
No fundamental analysis for SYBLEU INC. yet.
SYBLEU INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SYBLEU INC.
SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. SYBLEU INC. was incorporated in 2020 and is based in Bronx, New York. As of April 15, 2024, Sybleu Inc. operates as a sub…
Full company profileSYBLEU INC. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 4 quarters up to Dec 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
SYBLEU INC. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | 4.05K | 11.7K | 11.7K | 11.7K |
| Gross Profit | - | 4.05K | 11.7K | 11.7K | 11.7K |
| Operating Income | -46.3K | -88.3K | -56.4K | -149K | -276K |
| EBITDA | 46.3K | -88.3K | -1.88K | -2.81K | -262K |
| Net Income | -46.3K | -102K | -245K | -180K | -308K |
| EPS | 0.00 | -0.01 | -0.02 | -0.02 | -0.03 |
| Balance Sheet | |||||
| Total Assets | 8.55K | 200K | 76.4K | 61.0K | 304K |
| Total Liabilities | 11.3K | 204K | 326K | 327K | 694K |
| Shareholders' Equity | -2.78K | -4.61K | -250K | -266K | -390K |
| Cash & Short-term Investments | 5.05K | 14.3K | 66.9K | 36.8K | 175.00 |
| Total Debt | 11.3K | 8.92K | 140K | 140K | 489K |
| Cash Flow | |||||
| Operating Cash Flow | -75.3K | -88.3K | -78.5K | -101K | -85.2K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -75.3K | -88.3K | -78.5K | -101K | -85.2K |
| Ratios | |||||
| ROA | -541.6% | -51.0% | -321.2% | -295.6% | -101.2% |
| Net Profit Margin | - | -2,513.5% | -2,097.0% | -1,541.6% | -2,632.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SYBLEU INC. dividends
SYBLEU INC. has not paid dividends in the last 4 fiscal years.
Who owns SYBLEU INC.
- Insiders 7.61%
- Institutions 0.00%
- Public & others 92.40%
- Shares outstanding 10.6M
- Free float 3.05M
SYBLEU INC. company profile
- Company name
- SYBLEU INC.
- Ticker
- SYBE.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1034 Throggs Neck Expressway, Bronx, NY, United States, 10465
- Phone
- 800 807 4631
- Website
- -
About SYBLEU INC.
SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. SYBLEU INC. was incorporated in 2020 and is based in Bronx, New York. As of April 15, 2024, Sybleu Inc. operates as a subsidiary of Worldwide Holdings, LLC.
SYBLEU INC. management
2- Mr. Joseph G. VainiPresident, CEO, CFO, Secretary, Treasurer, Chief Accounting Officer & Chairman · born 1963
- Dr. Harry M. Lander MBA, Ph.D.Chief Scientific Officer · born 1965